



March 6, 2019

dB Diagnostic Systems, Inc.
% Scott Blood
Regulatory Consultant
MEDIcept, Inc.
200 Homer Avenue
Ashland, Massachusetts 01721

Re: K183201

Trade/Device Name: Hearing Healthcare Pro
Regulation Number: 21 CFR 874.1090
Regulation Name: Auditory Impedance Tester
Regulatory Class: Class II
Product Code: ETY
Dated: November 15, 2018
Received: November 19, 2018

Dear Scott Blood:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Srinivas Nandkumar -S

for Malvina Eydelman, M.D.

Director

Division of Ophthalmic and Ear, Nose,
and Throat Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K183201

Device Name

Hearing Healthcare Pro

Indications for Use (Describe)

The Hearing Healthcare Pro software will capture audiometry test results, and will allow user input of tympanometry results, physical examination results, and patient history. The software will summarize the inputted data and provide a “normal” or “abnormal” determination. If the decision is “abnormal”, the software can make a recommendation for clinical follow-up. The dB Diagnostic Systems, Inc. software is for adult use only and may be used by healthcare providers not normally trained or experienced in hearing, audiology, or otology, such as primary care providers.

The Hearing Healthcare Pro software is not intended to make a clinical diagnosis.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

510(k) SUMMARY
for the dB Diagnostic Systems, Inc.
Hearing Healthcare Pro
(per 21CFR 807.92)

1. SUBMITTER/510(k) HOLDER

dB Diagnostic Systems, Inc.

Official Contact: Dr. Steven Levine
Telephone: 203-984-0240

Consultant: Scott Blood
MEDIcept, Inc.
200 Homer Ave
Ashland, MA 01721

Date Prepared: November 15, 2018

2. DEVICE NAME

Proprietary Name: Hearing Healthcare Pro
Common/Usual Name: Hearing Healthcare Pro
Classification Name: Tester, Auditory Impedance
Regulation Number: 21 CFR 874.1090
Product Code: ETY
Classification Panel: Ear Nose & Throat
Device Classification: II

3. PREDICATE DEVICE

K171038 – Hearing Healthcare Pro manufactured by dB Diagnostic Systems, Inc.

4. DEVICE DESCRIPTION

The Hearing Healthcare (HHC) Pro is software designed to be used by healthcare providers (HCP) either trained and experienced in hearing, audiology, or otology, such as Ear, Nose, and Throat (ENT) doctors or not, such as primary care providers.

The HHC Pro software is not intended to make a clinical diagnosis. The HHC Pro software is a screening product. The software aggregates the inputted data and determines whether the person's hearing is considered normal or abnormal. If the results are abnormal, the software can either provide a recommendation for further clinical consultation with a licensed physician with expertise in Ear, Nose and Throat (ENT), or allow for an ENT-trained physician to enter their own recommendation in a blank text field. Further, the software can distinguish between symmetrical and asymmetrical sensorineural hearing loss; the former would be recommended to see an audiologist or an otolaryngologist who works with an audiologist, the latter would be recommended to an ENT clinical specialist.

The HHC Pro software compiles the hearing information previously available to physicians, classifies the data as normal or abnormal with respect to any measureable hearing loss, and identifies the presence of asymmetric hearing results. dB Diagnostics has chosen to validate the algorithm determining the difference between the symmetry and asymmetry of hearing loss as a greater than 20 dB difference between two ears at any test frequency (which are 250, 500, 1000, 2000, 4000, 6000, and 8000 Hz). The health care provider uses the HHC Pro to enter hand-held tympanometry results, limited clinical history, and limited physical examination findings, including a Rinne tuning fork test at 512Hz, to further identify patients who would benefit from an ENT evaluation.

The HHC Pro device comprises the HHC Pro Software. With the HHC Pro Software, dB Diagnostic Systems distributes the Amplitude T4 audiometer or the OTOpod audiometer, both manufactured by Auditdata A/S and collectively known as a "digital audiometer", a 512Hz Rinne tuning fork, and the Microsoft Surface Pro tablet preloaded with the Microsoft Windows 10 operating system and the HHC Pro Software. An Amplivox Otowave 102 Tympanometer may also be distributed with the HHC Pro software.

5. INTENDED USE / INDICATIONS FOR USE

The Hearing Healthcare Pro software will capture audiometry test results, and will allow user input of tympanometry results, physical examination results, and patient history. The software will summarize the inputted data and provide a "normal" or "abnormal" determination. If the decision is "abnormal", the software can make a recommendation for clinical follow-up. The dB Diagnostic Systems, Inc. software is for adult use only and may be used by healthcare providers not normally trained or experienced in hearing, audiology, or otology, such as primary care providers. The Hearing Healthcare Pro software is not intended to make a clinical diagnosis.

6. TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE

The modified HHC Pro device is similar to HHC Pro device currently cleared under K171038 in that both devices include software intended to compile hearing screening information. The software in both systems collects information from portable hearing testing equipment and provides output based on the information provided. Both capture audiometry results from a third-party pure tone audiometer and allows health care professionals (HCPs) to record patient history, otoscopic examination, and tympanometry results. Both provides recommendations for HCPs. Both devices are comprised only of software, an audiometer is sold with the device. Both devices are classified under FDA product code of ETY, Tester, Auditory Impedance.

The modified HHC Pro device differs from the HHC Pro device currently cleared under K171038 in the following areas (1) updating the Indications for Use statement to allow for the device usage by licensed Ear, Nose and Throat (ENT) physicians, (2) allowing for the distribution and use of the device with the OTOpod audiometer in addition to the Amplitude T4 audiometer already distributed with the cleared device, both known as “digital audiometer”(s), and (3) changes to the Recommendations field of the graphical user interface depending on the physician type using the device, and (4) adding the suggestion of bilateral symmetrical or asymmetrical sensorineural hearing loss to possible abnormal hearing test results.

The Hearing Healthcare Pro is substantially equivalent to the predicate device, as it has similar indications for use, and the exact same operational characteristics and fundamental technological characteristics as the HHC Pro device currently cleared under K171038.

7. PERFORMANCE TESTING

The dB Diagnostic Systems, Inc. HHC Pro has been designed and manufactured in compliance with the company’s performance specifications and the following FDA recognized consensus standards, voluntary industry standards, and FDA guidance documents:

- AAMI / ANSI / ISO 15223-1: 2012, Medical devices - symbols to be used with medical devices labels, labeling, and information to be supplied - part 1: general requirements. (General I (QS/RM))
- ISO 14971:2007, Medical devices - Application of risk management to medical devices

- ANSI S3.1-1999 (R2008) American National Standard Maximum Permissible Ambient Noise Levels for Audiometric Test Rooms
- FDA Guidance Document, General Principles of Software Validation; Final Guidance for Industry and FDA Staff, January 11, 2002
- FDA Guidance Document, Guidance for the content of Premarket Submission for Software in Medical Devices, May 11, 2005

The HHC Pro has been tested and is in compliance with internal software validation bench testing to compare the HHC Pro input test results to the gold standard, Board-Certified Otolaryngologist reviewers for equivalence in the output responses. In addition to the software validation bench testing performed, software verification was also conducted to FDA regulations, standards and guidance document requirements. The results of this testing conclude the software has met the design requirements.

8. CONCLUSION

The Hearing Healthcare Pro does not raise new issues of safety or effectiveness and is substantially equivalent to the predicate device.